TGFB1 and nonpapillary renal cell carcinoma: Overall, the findings highlight TGF-β1 as not only a biomarker of tumor aggressiveness and metastatic potential in ccRCC but also as a promising therapeutic target, especially in strategies aiming to enhance the efficacy of immune checkpoint blockade therapies [95].